{"id":"W2474545869","doi":"10.1182/blood.v106.11.446.446","title":"A Phase I Trial of the Small Molecule Pan-Bcl-2 Family Inhibitor GX15-070 Administered Intravenously (IV) Every 3 Weeks to Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL).","year":2005,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pharmacokinetics; Apoptosis; Pharmacology; Adverse effect; Chronic lymphocytic leukemia; Pharmacodynamics; Medicine; In vivo; Cmax; Bcl-2 family; Internal medicine; Immunology; Leukemia; Programmed cell death; Chemistry; Biology; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006478964,0.000883202,0.0008188284,0.0002701181,0.0002296978,0.0004587435,0.0004632158,0.0006836466,0.002375408],"category_scores_gemma":[0.0003210069,0.0003093504,0.0005580761,0.0001943347,0.0005944151,0.0004224177,0.0002671561,0.001759494,0.000492162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004494729,"about_ca_system_score_gemma":0.00058162,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004817397,"about_ca_topic_score_gemma":0.001090193,"domain_scores_codex":[0.9998275,0.00007869656,0.000007504399,0.0000248293,0.00001366017,0.00004770621],"domain_scores_gemma":[0.9997634,0.00004002206,0.00003680857,0.00001657228,0.000009595133,0.0001335281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5703564,0.06736527,0.01182716,0.0008046331,0.0008746906,0.0006987271,0.0004737115,0.004212022,0.1512111,0.0009527866,0.005189307,0.1860342],"study_design_scores_gemma":[0.255613,0.7190735,0.01218777,0.00003095567,0.0001752914,0.0003756012,0.00005159965,0.001471058,0.007676849,0.0001896771,0.003133093,0.00002158218],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99619,0.0009494099,0.0003157809,0.0001842775,0.00005662731,0.0008359868,0.0002625384,0.00005643979,0.001148967],"genre_scores_gemma":[0.9941447,0.0007788829,0.0007562992,0.0004805817,0.00006482572,0.0009541262,0.0009365654,0.00001319579,0.001870842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002375408,"threshold_uncertainty_score":0.007946491,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01670014330814229,"score_gpt":0.2672895160565252,"score_spread":0.2505893727483829,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}